Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Skye Bioscience’s SEC disclosures are dense with immunology terms, clinical endpoints, and cash-burn tables—precisely the data biotech investors need yet struggle to locate. Whether you’re searching for the latest Skye Bioscience insider trading Form 4 transactions or trying to untangle a 300-page annual report, complexity can slow critical decisions.
Stock Titan removes that friction. Our AI reviews every Skye Bioscience quarterly earnings report 10-Q filing, 8-K material updates, and Skye Bioscience proxy statement executive compensation section, then delivers plain-English explanations. Need Skye Bioscience Form 4 insider transactions real-time? Alerts arrive seconds after EDGAR posts. Want the Skye Bioscience annual report 10-K simplified? One click highlights nimacimab trial costs, R&D spend, and cash runway. It’s Skye Bioscience SEC filings explained simply—powered by AI.
Use the platform to move from documents to decisions:
- Skye Bioscience executive stock transactions Form 4 alerts for monitoring leadership confidence
- 10-Q drill-downs that fuel Skye Bioscience earnings report filing analysis and trend comparisons
- Skye Bioscience 8-K material events explained, including pivotal clinical-trial readouts
- Quick tips for understanding Skye Bioscience SEC documents with AI
From R&D milestones to valuation drivers, Stock Titan gives you the context you need—so you can focus on strategy, not document hunting.
Insider sales by a director/10% owner over two days. Andrew J. Schwab, reporting as a director and a 10% owner through affiliated 5AM entities, reported multiple open-market dispositions of Skye Bioscience (SKYE) common stock on 08/21/2025 and 08/22/2025. The filings show weighted-average sale prices in two ranges: $3.55–$3.69 for 08/21 and $3.30–$3.59 for 08/22. Reported individual dispositions total 58,642; 2,314; 163,979; and 6,470 shares across the two days, with ownership reported on various lines as indirect through 5AM Ventures II, 5AM Co-Investors II, and 5AM Ventures VII. The form is signed by Mr. Schwab on 08/22/2025.
Skye Bioscience insiders reported multiple sales of common stock on August 21-22, 2025. Entities affiliated with 5AM sold a total of 231,405 shares across two days at weighted-average prices of $3.57 (sales on 08/21) and $3.42 (sales on 08/22), with transaction prices in footnotes ranging from $3.30 to $3.69. After the reported transactions, the filing shows beneficial ownership positions including 1,621,043, 63,963, 1,457,064, 57,493 and a block of 8,167,206 shares held indirectly by 5AM-affiliated entities. The report is signed by the applicable 5AM entities and individual managing members.
Schonfeld Strategic Advisors LLC filed an amendment to a Schedule 13G reporting ownership of 1,115,939 shares of Skye Bioscience, Inc. common stock, representing 3.60% of the class. The filing states those shares are held for the ordinary course of business and not for the purpose of influencing control. Schonfeld reports sole voting and dispositive power over the reported shares and notes that some shares are held in separately managed accounts for clients who retain the right to dividends or sale proceeds.
FAQ
What is the current stock price of Skye Bioscience (SKYE)?
What is the market cap of Skye Bioscience (SKYE)?
